These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28500398)

  • 21. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers.
    Venesio T; Siravegna G; Bardelli A; Sapino A
    Pathobiology; 2018; 85(1-2):146-154. PubMed ID: 28614831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
    Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
    Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
    Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
    Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of circulating tumor DNA to monitor metastatic breast cancer.
    Dawson SJ; Tsui DW; Murtaza M; Biggs H; Rueda OM; Chin SF; Dunning MJ; Gale D; Forshew T; Mahler-Araujo B; Rajan S; Humphray S; Becq J; Halsall D; Wallis M; Bentley D; Caldas C; Rosenfeld N
    N Engl J Med; 2013 Mar; 368(13):1199-209. PubMed ID: 23484797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient.
    Welter L; Xu L; McKinley D; Dago AE; Prabakar RK; Restrepo-Vassalli S; Xu K; Rodriguez-Lee M; Kolatkar A; Nevarez R; Ruiz C; Nieva J; Kuhn P; Hicks J
    Cold Spring Harb Mol Case Stud; 2020 Dec; 6(6):. PubMed ID: 33203646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.
    Callens C; Driouch K; Boulai A; Tariq Z; Comte A; Berger F; Belin L; Bièche I; Servois V; Legoix P; Bernard V; Baulande S; Chemlali W; Bidard FC; Fourchotte V; Salomon AV; Brain E; Lidereau R; Bachelot T; Saghatchian M; Campone M; Giacchetti S; Zafrani BS; Cottu P
    Genome Med; 2021 Mar; 13(1):44. PubMed ID: 33722295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
    Pezo RC; Chen TW; Berman HK; Mulligan AM; Razak AA; Siu LL; Cescon DW; Amir E; Elser C; Warr DG; Sridhar SS; Yu C; Wang L; Stockley TL; Kamel-Reid S; Bedard PL
    Breast Cancer Res Treat; 2018 Feb; 168(1):159-168. PubMed ID: 29177603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical utility of circulating cell-free DNA in advanced colorectal cancer.
    Pereira AAL; Morelli MP; Overman M; Kee B; Fogelman D; Vilar E; Shureiqi I; Raghav K; Eng C; Manuel S; Crosby S; Wolff RA; Banks K; Lanman R; Talasaz A; Kopetz S; Morris V
    PLoS One; 2017; 12(8):e0183949. PubMed ID: 28850629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
    Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer.
    Parsons HA; Beaver JA; Cimino-Mathews A; Ali SM; Axilbund J; Chu D; Connolly RM; Cochran RL; Croessmann S; Clark TA; Gocke CD; Jeter SC; Kennedy MR; Lauring J; Lee J; Lipson D; Miller VA; Otto GA; Rosner GL; Ross JS; Slater S; Stephens PJ; VanDenBerg DA; Wolff AC; Young LE; Zabransky DJ; Zhang Z; Zorzi J; Stearns V; Park BH
    Clin Cancer Res; 2017 Jan; 23(2):379-386. PubMed ID: 27489289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
    Wang JF; Pu X; Zhang X; Chen K; Xi Y; Wang J; Mao X; Zhang J; Heymach JV; Antonoff MB; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Meng QH; Shaw KR; Eterovic AK; Fang B
    Cancer; 2018 Mar; 124(5):1061-1069. PubMed ID: 29178133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
    Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
    PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer.
    Silveira C; Sousa AC; Corredeira P; Martins M; Sousa AR; Da Cruz Paula A; Selenica P; Brown DN; Golkaram M; Kaplan S; Zhang S; Liu L; Weigelt B; Reis-Filho JS; Costa L; Carmo-Fonseca M
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.
    Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Patel SP; Harismendy O; Ikeda M; Parker BA; Kurzrock R
    Clin Cancer Res; 2016 Nov; 22(22):5497-5505. PubMed ID: 27185373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers.
    Santa-Maria CA; Kruse M; Raska P; Weiss M; Swoboda A; Mutonga MB; Abraham J; Jain S; Nanda R; Montero AJ
    Breast Cancer Res Treat; 2017 Nov; 166(1):179-184. PubMed ID: 28752189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
    Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.